Candelaria Gomez-Manzano
University of Texas MD Anderson Cancer Center
CancerPathologyVirologyImmunologyAutophagyIn vivoAdenoviridaeOncolytic adenovirusGliomaBrain tumorStem cellVirotherapyCancer researchMedicineCell cultureOncolytic virusBiologyImmune systemCell biologyCancer cell
203Publications
50H-index
13kCitations
Publications 208
Newest
#1Yuzaburo ShimizuH-Index: 3
#2Joy GuminH-Index: 28
Last. Juan FueyoH-Index: 58
view all 0 authors...
OBJECTIVE Delta-24-RGD is an oncolytic adenovirus that is capable of replicating in and killing human glioma cells. Although intratumoral delivery of Delta-24-RGD can be effective, systemic delivery would improve its clinical application. Bone marrow-derived human mesenchymal stem cells (BM-hMSCs) obtained from healthy donors have been investigated as virus carriers. However, it is unclear whether BM-hMSCs can be derived from glioma patients previously treated with marrow-toxic chemotherapy or w...
Source
Source
#1S. P. Gupta (University of Texas MD Anderson Cancer Center)
#1Sumit GuptaH-Index: 54
Last. Yanhua Yi (University of Texas MD Anderson Cancer Center)H-Index: 1
view all 14 authors...
Diffuse Intrinsic Pontine Glioma (DIPG) is the leading cause of pediatric death by brain tumors with a median survival of only 9 months, in spite of the current standard of therapy which includes radiation. The purpose of our study is to explore the use of oncolytic adenoviruses as a new therapeutic modality. Our group is leading a phase I clinical trial in naive DIPGs treated with the oncolytic adenovirus Delta-24-RGD, also named DNX-2401 (NCT03178032), which results are still pending. Of inter...
Source
#1Dong Ho ShinH-Index: 3
#2Teresa NguyenH-Index: 8
Last. Juan FueyoH-Index: 58
view all 10 authors...
Source
Background null Glioblastoma (GBM) is a devastating primary brain tumor with a highly immunosuppressive tumor microenvironment, and treatment with oncolytic viruses (OVs) has emerged as a promising strategy for these tumors. Our group constructed a new OV named Delta-24-ACT, which was based on the Delta-24-RGD platform armed with 4-1BB ligand (4-1BBL). In this study, we evaluated the antitumor effect of Delta-24-ACT alone or in combination with an immune checkpoint inhibitor (ICI) in preclinical...
Source
#1Teresa NguyenH-Index: 8
#2Dong Ho ShinH-Index: 3
Last. Candelaria Gomez-ManzanoH-Index: 50
view all 11 authors...
Source
#2Teresa NguyenH-Index: 8
Last. Marta M. AlonsoH-Index: 36
view all 12 authors...
Source
#1Hong JiangH-Index: 52
#2Teresa NguyenH-Index: 8
Last. Juan FueyoH-Index: 58
view all 9 authors...
Source
Last. Filipa Godoy-VitorinoH-Index: 14
view all 7 authors...
Source
#1Juan Fueyo (University of Texas MD Anderson Cancer Center)H-Index: 58
#2Candelaria Gomez-Manzano (University of Texas MD Anderson Cancer Center)H-Index: 50
Last. Marta M. AlonsoH-Index: 36
view all 4 authors...
Source